BUZZ-Incyte rises after antibody therapy shows potential in rare blood cancers

Reuters12-08
BUZZ-Incyte rises after antibody therapy shows potential in rare blood cancers

** Shares of drugmaker Incyte INCY.O up 2.4% at $105 premarket

** INCY said on Sunday its experimental antibody therapy, INCA033989, showed significant reductions in spleen size and symptoms in patients with a type of rare blood cancer

** The therapy is being tested in patients with myelofibrosis (MF), that scars the bone marrow, and in those with essential thrombocythemia $(ET)$, a disorder where the marrow makes too many platelets leading to an increased risk of blood clots or bleeding

** The treatment, tested alone and with cancer drug Jakafi, improved anemia and reduced CALR mutations in myelofibrosis patients, suggesting it may alter the course of the disease, early trial data showed

** Leerink Partners estimates that Incyte's mCALR program could generate about $870 million in peak annual sales for myelofibrosis and roughly $1 billion for essential thrombocythemia

** As of last close, stock up 48.4% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment